Houlihan Lokey Advises ClearView

Houlihan Lokey is pleased to announce that ClearView Healthcare Partners (ClearView), the leading provider of strategic consulting services to global innovators in the life sciences, has received an investment from GHO Capital (GHO). The transaction closed on August 31, 2021.

Headquartered in Boston with offices in New York, San Francisco, London, and Zurich, ClearView Healthcare Partners is the leading life sciences strategic consultancy. ClearView is known for combining its deep and diversified therapeutic expertise with business insights to deliver actionable recommendations to its customers in support of growth and innovation strategy. ClearView supports drug sponsors throughout the development and commercialization process and guides overall approaches to clinical and commercial portfolio development. ClearView services a wide range of market-leading innovators across the Big Pharma/biopharma, diagnostics, medtech, and life science services/tools segments.

Led by its founders Rich Mynahan, Steve Chao, and Kevin Richard, alongside a world-class leadership team, ClearView is well positioned to enhance its market-leading position within life sciences consulting, an industry exhibiting accelerating secular growth. Against a backdrop of industry fragmentation, the company will significantly benefit from GHO’s resources, expertise, and global reach in building its European practice and driving geographic expansion via M&A.

ClearView is set to continue driving significant organic growth, cross-selling emerging solutions that include data analytics, and pricing and market access to expand an existing client base while leveraging relationships to broaden capabilities across the small- and mid-cap life sciences.

GHO Capital is a leading specialist healthcare investment advisor based in London. The firm seeks to partner with strong management teams focused on improving the efficiency of healthcare delivery to enable better, faster, more accessible healthcare.

GHO invested an undisclosed amount in ClearView from RLH Equity Partners for a majority stake, with founding partners and leadership retaining a material ownership position in the firm.

Houlihan Lokey served as the financial advisor to ClearView and assisted in structuring and negotiating the transaction on its behalf. This deal highlights Houlihan Lokey’s leading experience in the pharma services space and represents the firm’s ninth transaction in this sector since 2019.